Recombinant protein based on the extracellular domain of African swine fever virus CD2v protein and its construction method and application

By inserting recombinant proteins with specific tags or motifs into the ectodomain of the CD2v protein of African swine fever virus, a detection method for indirect ELISA was constructed, and the problem of insufficient sensitivity and specificity of ASFV diagnostic kits in the prior art was solved, and the problem of insufficient sensitivity and specificity of ASFV diagnostic kits was achieved. Higher recognition capabilities and wider applications.

CN115073609BActive Publication Date: 2024-11-26湖南派智生物科技有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210401397.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-18
Publication Date
2024-11-26
Estimated Expiration
2042-04-18

AI Technical Summary

Technical Problem

The existing African swine fever virus ASFV diagnostic kits have insufficient sensitivity and specificity in the face of serotype and genotype diversity, making it difficult to effectively monitor and control viral transmission.

Method used

Using recombinant proteins based on the ectocyte domain of the CD2v protein of African swine fever virus, the GCN4 or c-Jun motif is inserted at its N-terminal end or the GCN4 or c-Jun motif is inserted at its N-terminal end, and the detection kit and detection method are constructed to improve the ASFV Antibody recognition ability.

Benefits of technology

It significantly improves the recognition ability of ASFV positive serum samples, achieves higher sensitivity and specificity, can distinguish ASFV type 4 and 8 serotypes, and reduces cross-reaction with other porcine pathogens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115073609B_ABST
    Figure CN115073609B_ABST
Patent Text Reader

Abstract

The present invention discloses a recombinant protein based on the extracellular domain of the African swine fever virus CD2v protein, including: the extracellular domain of the African swine fever virus CD2v protein, an MBP tag protein is inserted into the N-terminus of the extracellular domain of the African swine fever virus CD2v protein, or a GCN4 motif or a c-Jun motif is inserted into the C-terminus of the extracellular domain of the African swine fever virus CD2v protein. Also disclosed are a construction method of the recombinant protein, an application in establishing an indirect ELISA detection method, and an indirect ELISA detection kit and a detection method. The recombinant protein of the present invention can be soluble expressed and purified in mammalian, baculovirus and Escherichia coli expression systems, has the potential to distinguish wild-type toxins from CD2v-deficient strains, has serum specificity, and distinguishes ASFV type 4 from type 8 serotypes, and can detect ASFV antibodies based on the ELISA of the CD2v extracellular domain, has higher sensitivity and specificity, and is widely used.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biological detection, and in particular relates to several recombinant proteins based on the extracellular domain of African swine fever virus CD2v protein and a construction method thereof, and applications thereof in establishing an indirect ELISA detection kit or an indirect ELISA detection method. Background Art

[0002] African swine fever (ASF) is an acute infectious disease that threatens the global pig industry. African swine fever virus (ASFV) is a double-stranded DNA (dsDNA) virus with a genome size of 170-190 kbp and 150 open reading frames (ORFs). Mass spectrometry analysis found that there are at least 40 viral proteins in the five viral domains of the virus particle, namely the outer envelope, capsid, inner envelope, nucleocapsid and nucleolus, arranged from the outside to the inside. According to the molecular genotyping of p72 (B646L), ASFV has 23 different genotypes. A simple serotyping method is based on the gene sequence of CD2v (EP402R) or c type lectin (EP153) protein. CD2v and c type lectin are necessary and sufficient conditions for mediating the serological specificity of the hemadsorption inhibition test (HAI). ASFV is currently divided into 8 serotypes based on HAI.

[0003] According to the molecular characteristics of p72 and CD2v, the pathogenic strain belongs to genotype II and serogroup 8, which is highly virulent and contagious in domestic pigs. In domestic pigs, clinical symptoms of ASFV include high fever, hemorrhage, ataxia and severe depression, and the mortality rate is close to 100%. In the absence of a commercial ASFV vaccine, monitoring of ASFV is very important in disease prevention and control.

[0004] In Spain, ASFV serological screening of a large number of clinical samples is considered a convenient and effective method for disease detection and eradication. The detection of ASFV antibodies is currently mainly carried out internationally using three commercial kits (IDvet, Svanova and Ingenasa). ID vet is an indirect ELISA kit based on three recombinant proteins p32 (p30), p72 and p62; Svanova is an indirect ELISA kit based on recombinant protein p30; Ingenasa is a competitive ELISA kit based on anti-p72 monoclonal antibody (mAb). Although all of these commercial kits can be used for the detection of ASFV IgG, due to the large number of ASFV serotypes and genotypes and their rapid spread, in order to control the spread of the disease, ASFV diagnostic kits with higher sensitivity and specificity, as well as highly sensitive and widely used serological detection methods are urgently needed to strengthen surveillance. Summary of the invention

[0005] The technical problem to be solved by the present invention is to overcome the deficiencies and defects mentioned in the above background technology and provide several recombinant proteins based on the extracellular domain of African swine fever virus CD2v protein and their construction methods and applications, indirect ELISA kits and their detection methods.

[0006] In order to solve the above technical problems, the technical solution proposed by the present invention is:

[0007] A recombinant protein based on the extracellular domain of African swine fever virus CD2v protein, comprising: the extracellular domain of African swine fever virus CD2v protein, an MBP tag protein inserted into the N-terminus of the extracellular domain of African swine fever virus CD2v protein, or a GCN4 motif or a c-Jun motif inserted into the C-terminus of the extracellular domain of African swine fever virus CD2v protein.

[0008] Furthermore, the African swine fever virus CD2v protein extracellular domain is the CD2v protein extracellular domain of ASFV type 4 or ASFV type 8, wherein: the amino acid sequence of the ASFV type 4 CD2v protein extracellular domain is shown in SEQ ID NO: 9, and the amino acid sequence of the ASFV type 8 CD2v protein extracellular domain is shown in SEQ ID NO: 10.

[0009] Furthermore, the amino acid sequence of the recombinant protein is as shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, wherein: the amino acid sequence of the recombinant protein formed by inserting the MBP tag protein into the N-terminus of the extracellular domain of the CD2v protein is as shown in SEQ ID NO: 1, the amino acid sequence of the recombinant protein formed by inserting the GCN4 motif into the C-terminus of the extracellular domain of the CD2v protein is as shown in SEQ ID NO: 2, and the amino acid sequence of the recombinant protein formed by inserting the c-Jun motif into the C-terminus of the extracellular domain of the CD2v protein is as shown in SEQ ID NO: 3.

[0010] CD2v is located in the outer membrane of the virus particle and plays an important role in virus transmission, immune regulation and escape. Homologous CD2v can produce protective immune responses after immunizing animals, and prevent homologous ASFV infection when responding to ASFV chimeric virus challenges, suggesting that CD2v can provide serotype-specific protective immunity. In addition, CD2v has strong immunogenicity and can produce humoral and cellular immunity. Therefore, the present invention has been found through research that it also has the potential to be used as a candidate target for serological diagnosis and to protect ASFV antigens, and has the potential for application in distinguishing serotypes 4 and 8 in clinical samples, and glycosylation modification of the CD2v extracellular domain is necessary for ELISA detection of African swine fever virus (ASFV) antibodies.

[0011] Based on a general inventive concept, the present invention also provides a method for constructing a recombinant protein based on the extracellular domain of African swine fever virus CD2v protein, comprising the following steps: fusing a nucleotide fragment encoding the extracellular domain of African swine fever virus CD2v protein with a nucleotide fragment encoding an MBP tag protein, a GCN4 motif or a c-Jun motif, and then subcloning the resultant expression plasmid into a vector, and expressing the obtained expression plasmid in 293F cells, baculovirus or Escherichia coli to obtain the recombinant protein.

[0012] Furthermore, the sequence of the nucleotide fragment encoding the extracellular domain of the African swine fever virus CD2v protein is as shown in SEQ ID NO: 4 or SEQ ID NO: 5, wherein: the sequence of the nucleotide fragment encoding the extracellular domain of the ASFV 4 type CD2v protein is as shown in SEQ ID NO: 4, and the sequence of the nucleotide fragment encoding the extracellular domain of the ASFV 8 type CD2v protein is as shown in SEQ ID NO: 5.

[0013] Furthermore, the sequence of the nucleotide fragment encoding the MBP tag protein is shown in SEQ ID NO: 6, the sequence of the nucleotide fragment encoding the GCN4 motif is shown in SEQ ID NO: 7, and the sequence of the nucleotide fragment encoding the c-Jun motif is shown in SEQ ID NO: 8.

[0014] Based on a general inventive concept, the present invention also provides a use of the above recombinant protein in establishing an indirect ELISA detection kit or an indirect ELISA detection method.

[0015] Furthermore, the process of establishing an indirect ELISA detection kit or an indirect ELISA detection method comprises the following steps: using the recombinant protein described in any one of claims 1-3 or obtained by the construction method of any one of claims 4-6 as a coating antigen, diluting it with PBS and adding it to the wells of the ELISA plate for coating overnight, then blocking, serum incubation, IgG and IgA HRP enzyme-labeled secondary antibody incubation, color development reaction, and then using an enzyme reader to measure the absorbance of the reaction solution at 450nm, and calculating the critical value based on the ELISA data as a standard for subsequent sample positive and negative judgment, which is used to establish an indirect ELISA detection kit or an indirect ELISA detection method.

[0016] Based on a general inventive concept, the present invention also provides an indirect ELISA detection kit, comprising: a 96-well detachable enzyme-linked reaction plate coated with an antigen, a positive control serum, a negative control serum, a horseradish peroxidase-labeled goat anti-pig secondary antibody (purchased from KPL, item number 14-14-06), a 10-fold concentrated PBST washing solution, a TMB color developing solution (purchased from KPL, item number 5120-0076) and a stop solution, wherein the antigen is the recombinant protein.

[0017] Furthermore, the positive control serum is the immune serum of the recombinant protein, the negative control serum is the pig serum without specific pathogens, the goat anti-pig secondary antibody labeled with horseradish peroxidase is obtained by diluting its stock solution at a volume of 1:7000, the 10-fold concentrated PBST washing solution is a phosphate buffer solution with a pH value of 7.4 and a concentration of 0.01 mol / L containing 0.05% Tween 20, and the stop solution is a 2 mol / L sulfuric acid solution.

[0018] Based on a general inventive concept, the present invention also provides an indirect ELISA detection method, comprising the following steps: using the recombinant protein described in any one of claims 1 to 3 or obtained by the construction method of any one of claims 4 to 6 as a coating antigen, diluting it with PBS and adding it to the wells of the ELISA plate for coating overnight, then blocking, incubating the serum sample to be tested, incubating with the HRP enzyme-labeled antibody of IgG or IgA, and color development, and then measuring the absorbance of the reaction solution at 450nm with an enzyme reader, and judging the test result with reference to the OD450 critical value standard of the test item, OD450 ≥ critical value is judged as positive, and OD450 < critical value is judged as negative.

[0019] Furthermore, the recombinant protein is obtained by fusing a nucleotide fragment encoding the extracellular domain of the African swine fever virus CD2v protein with a nucleotide fragment encoding the c-Jun motif, subcloning them into a vector, and expressing the resulting expression plasmid in 293F cells, namely CD2v-ED-c-Jun-293.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] 1. The recombinant protein of the present invention has an MBP tag protein inserted into the N-terminus of the extracellular domain of the African swine fever virus CD2v protein and a GCN4 motif or a c-Jun motif inserted into the C-terminus. It can be soluble expressed and purified in mammalian, baculovirus and Escherichia coli expression systems, has the potential to distinguish between wild-type and CD2v-deficient strains, has serum specificity, and can distinguish between ASFV type 4 and type 8 serotypes. It can also detect ASFV antibodies (IgG and IgA) based on ELISA of the CD2v extracellular domain.

[0022] 2. The recombinant protein of the present invention, after adding GCN4 or c-Jun to the CD2v extracellular domain, is used for ELISA. Compared with the conventional CD2v extracellular domain, it significantly improves the recognition ability of ASFV positive serum samples and can be used to establish an indirect ELISA detection kit or an indirect ELISA detection method.

[0023] 3. The indirect ELISA detection kit and detection method of the present invention have higher sensitivity and specificity and are widely used. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 It is the extracellular domain of MBP-CD2v purified after preparation from different expression systems analyzed by SDS-PAGE; wherein, M: protein molecular weight Marker; 1: MBP-CD2v-ED-E (about 65kDa); 2: MBP-CD2v-ED-H5 (about 75kDa); 3: MBP-CD2v-ED-293 (about 105kDa).

[0026] Figure 2 The coated antigens were screened based on different types of recombinant CD2v extracellular domains; CD2v-ED-293 expressed by 293F cells, CD2v-ED-H5 expressed by baculovirus system, CD2v-ED-E expressed by Escherichia coli expression system (a), and CD2v-ED-c-Jun-293 and CD2v-ED-GCN4-293 expressed by 293F cells (b) were used as antigens to detect ASFV-positive serum samples respectively; P values ​​were calculated by two-tailed test, *p<0.05, **p<0.01, ***p<0.001.

[0027] Figure 3 Different types of ASFV antibodies and their specificity were analyzed; anti-ASFV, PCV2, PRV, PEDV, PRRSV and CSFV positive sera were tested for (a) IgG and (b) IgA using ELISA based on the CD2v extracellular domain.

[0028] Figure 4 The established ELISA was used to detect IgG in standard serum at different dilution multiples of the wild-type strain and the CD2v gene-deficient strain; the P value was calculated by a two-tailed test, ****p<0.0001.

[0029] Figure 5 It is the result of serotype-specific analysis and cross-reaction with other common swine pathogens; anti-ASFV (type 8), PCV2, PRV, PEDV, PRRSV and CSFV positive sera were detected using an ELISA method based on the detection of IgG for the extracellular domain of type 4 CD2v. DETAILED DESCRIPTION

[0030] In order to facilitate the understanding of the present invention, the present invention will be described more comprehensively and meticulously below in conjunction with the accompanying drawings and preferred embodiments of the present invention, but the protection scope of the present invention is not limited to the following specific embodiments.

[0031] Unless otherwise defined, all professional terms used below have the same meanings as those generally understood by those skilled in the art. The professional terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of protection of the present invention.

[0032] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0033] Example:

[0034] A recombinant protein based on the extracellular domain of the CD2v protein of African swine fever virus, comprising: the extracellular domain of the CD2v protein of African swine fever virus, and an MBP tag protein inserted into its N-terminus, and a GCN4 motif or a c-Jun motif at its C-terminus. The amino acid sequence of the recombinant protein formed by the fusion of the CD2v protein extracellular domain and the MBP tag protein is shown in SEQ ID NO: 1, the amino acid sequence of the recombinant protein formed by the fusion of the CD2v protein extracellular domain and the GCN4 motif is shown in SEQ ID NO: 2, and the amino acid sequence of the recombinant protein formed by the fusion of the CD2v protein extracellular domain and the c-Jun motif is shown in SEQ ID NO: 3.

[0035] The construction and screening process of the recombinant protein is as follows:

[0036] 1. Experimental Method

[0037] 1. Plasmid construction

[0038] The sequences of ASFV4 type BA71 CD2v (GenBank accession number AKO62740) and ASFV serotype 8 type Pig / HLJ / 18CD2v (GenBank accession number QBH90546) were downloaded from the NCBI (National Center of Biotechnology Information) website, and the nucleotide fragments were optimized for human codons to facilitate expression in 293F cells. In addition, codon optimization of other expression systems was performed separately, and the nucleotide fragments encoding MBP tags, GCN4 and c-Jun were fused to the ASFV 8 type CD2v extracellular domain to facilitate expression in mammalian, baculovirus and Escherichia coli expression systems. All ASFV nucleotide fragments were synthesized by a commercial company (GenScript) and subcloned into a vector.

[0039] Among them, the nucleotide sequence encoding the ASFV 4 type CD2v extracellular domain is shown in SEQ ID NO: 4, the nucleotide sequence encoding the ASFV 8 type CD2v extracellular domain is shown in SEQ ID NO: 5, and the nucleotide sequences of the nucleotide fragments encoding the MBP tag, GCN4 and c-Jun are shown in SEQ ID NO: 6-8 respectively. The amino acid sequence of the ASFV 4 type CD2v extracellular domain is shown in SEQ ID NO: 9, and the amino acid sequence of the ASFV 8 type CD2v extracellular domain is shown in SEQ ID NO: 10.

[0040] 2. Protein expression preparation

[0041] (1) Preparation of 293 expression system

[0042] Several recombinant proteins were prepared in different expression systems to obtain soluble recombinant proteins of CD2v extracellular domain prepared in different expression systems. For serum type 4 and 8 recombinant proteins CD2v extracellular domain (CD2v-ED) and CD2v extracellular domain fused with MBP tag (MBP-CD2v-ED-293), GCN4 (CD2v-ED-GCN4-293) and c-Jun (CD2v-ED-c-Jun-293) recombinant proteins (serum type 8), mammalian expression systems were used for recombinant expression. The main process is to prepare the expression plasmids of different recombinant proteins using a plasmid large-scale extraction kit (OMEGA), extract high-purity plasmids without endotoxin, and measure the concentration. The 293F cells were transfected with endotoxin-free plasmid DNA and incubated at 5% CO 2 The cells were cultured at 37°C and 140 rpm, and the supernatant was collected after culturing in SMM 293T-II expression medium (Sino Biological Corporation) for 5-7 days.

[0043] (2) Preparation of insect baculovirus expression system

[0044] The recombinant protein (serotype 8) of CD2v extracellular domain fused to MBP tag (MBP-CD2v-ED-H5) was also expressed in the baculovirus expression system and then expressed using the pFastBac baculovirus expression system (Invitrogen). Briefly, the constructed recombinant plasmid was transposed into DH10Bac competent cells to produce recombinant bacmid DNA. The recombinant bacmid DNA was transfected into Sf9 cells to produce recombinant baculovirus and amplified. The recombinant baculovirus was then infected with High Five cells cultured in SIM HF (Sino Biological) medium, cultured at 27°C and 130 rpm, and the supernatant was collected after 72 h.

[0045] (3) Preparation of E. coli expression system

[0046] The main steps for expressing the recombinant protein (serotype 8) of the CD2v extracellular domain fused to the MBP tag (MBP-CD2v-ED-E) in the E. coli expression system are as follows: the recombinant plasmid is transformed into BL21 (DE3) competent cells, and after a large amount of induction expression by expanding the culture volume, the supernatant is removed after centrifugation at 5000g for 10 minutes, the bacterial precipitate is harvested, and then the culture is heated in 50mM NaHCO3 solution. 2 PO 4 ·2H 2 O, 20mM imidazole, 10mM Tris base, 300mM NaCl and 0.1% Triton X-100 buffer. After ultrasonic disruption of the bacteria on ice, centrifugation at 4°C and 20000g for 20min, the supernatant was harvested to achieve soluble expression. The five recombinant proteins were derived from mammalian expression systems, baculovirus expression systems and Escherichia coli expression systems, respectively, and all of them could be purified from the supernatant using a nickel column (GE Healthcare). The purified proteins were concentrated and dissolved in 10mM PBS, pH 7.4 for storage.

[0047] 3. Screening of antigens coated with ELISA

[0048] In order to determine which system of CD2v recombinant protein expressed by mammalian expression system, baculovirus expression system and E. coli expression system is more suitable for establishing ELISA protocol, the serum incubation time, HRP enzyme-labeled secondary antibody incubation time and TMB reaction time are set and determined according to conventional methods. The specific operation steps of other experimental methods are as follows:

[0049] (1) Coating: The recombinant proteins obtained from three different expression systems were diluted with PBS (10 mM, pH 7.4), added to a 96-well ELISA plate (Corning), and coated at 4°C overnight.

[0050] (2) Blocking: After coating, discard the liquid in the wells, wash 5 times with 300 μL PBST, block with BSA, incubate at room temperature for 3 h, wash 5 times with PBST, air-dry and seal, and store at 2-8°C away from light.

[0051] (3) Serum incubation: Add 100 μL of diluted porcine serum to each well and incubate at room temperature for 1 h.

[0052] (4) Incubation with HRP enzyme-labeled secondary antibody: After serum incubation, wash with PBST for 5 times, add 100 μL of diluted HRP enzyme-labeled goat anti-swine IgG (h+L) (KPL Company) into the wells, and incubate at room temperature for 30 minutes.

[0053] (5) Color development reaction: After incubation with HRP enzyme-labeled secondary antibody, the wells were washed 5 times with PBST, 50 μL TMB color development solution (KPL) was added to each well, and 2 M H 2 SO 4 Stop solution and measure the absorbance of each reaction well at 450nm using an enzyme reader.

[0054] 4. Determination of the method for detecting IgG and IgA

[0055] The recombinant protein with the determined coating concentration was diluted with PBS (10 mM, pH 7.4), and then added to a 96-well ELISA plate (Corning) and coated overnight at 4°C. The following experimental steps were then performed:

[0056] (1) Blocking: After coating, discard the liquid in the wells, wash 5 times with 300 μL PBST, block with BSA, incubate at room temperature for 3 h, wash 5 times with PBST, air-dry, seal, and store at 2-8°C away from light.

[0057] (2) Serum incubation: Add 100 μL of diluted porcine serum to each well and incubate at room temperature for 1 h.

[0058] (3) Incubation with HRP-labeled secondary antibody: After serum incubation, wash with PBST for 5 times, add 100 μL of diluted HRP-labeled goat anti-swine IgG (h+L) (KPL) and HRP-labeled goat anti-swine IgA (H+L) (Abcam, UK) into different wells and incubate at room temperature for 30 min for subsequent detection of IgG and IgA.

[0059] (4) Color development reaction: After incubation with HRP enzyme-labeled secondary antibody, the wells were washed 5 times with PBST, 50 μL TMB color development solution (KPL) was added to each well, and 2 M H 2 SO 4 Stop solution, use a microplate reader to measure the absorbance of each reaction well at 450nm, and calculate the critical value based on the ELISA data as the standard for subsequent sample positive and negative judgment.

[0060] 5. Specificity test

[0061] 50 ASFV clinical negative control sera (collected before the outbreak of African swine fever in China in 2018) were selected and the established ELISA method was used to detect IgG and IgA. The specificity of the ELISA method was determined based on the absorbance results and critical values.

[0062] 6. Cross-reactivity test

[0063] Clinical serum samples that have been confirmed to be positive for porcine circovirus type 2 (PCV2), pseudorabies virus (PRV), porcine epidemic diarrhea (PEDV), porcine reproductive and respiratory syndrome virus (PRRSV) and classical swine fever virus (CSFV) antibodies were tested using the established ELISA method. Based on the absorbance results and critical values ​​obtained, it was determined whether the positive sera of different pathogens could react with the recombinant protein coated on the ELISA plate, and the cross-reaction of this scheme for detecting ASFV CD2v antibody IgG and IgA was determined respectively.

[0064] 7. Compliance test

[0065] A total of 51 ASFV-positive clinical sera and 45 clinically negative sera provided by the Hunan Provincial Animal Disease Prevention and Control Center were selected for IgG and IgA testing using the ELISA method we established. The results were determined based on the absorbance results and the critical value, and the consistency rate of IgG and IgA testing in the identification of clinical serum samples was calculated.

[0066] 8. Distinguishing antibodies between wild-type virus and CD2v-deficient strains based on ELISA

[0067] Two standard serum samples immunized with ASFV type 8 wild strain and CD2v gene-deficient strain purchased from the China Veterinary Drug Administration were selected as standard positive controls. IgG was detected using our kit, and the results were determined based on the absorbance results and the critical value to determine the ability to distinguish different strains.

[0068] 9. Distinguishing ASFV serotypes based on ELISA

[0069] The purified CD2v serotype 4 recombinant protein was used as the coating antigen, diluted with PBS (10 mM, pH 7.4), and then added to a 96-well ELISA plate (Corning) and coated overnight at 4°C. The following experimental steps were then performed:

[0070] (1) Blocking: After coating, discard the liquid in the wells, wash 5 times with 300 μL PBST, and then block with BSA. Incubate at room temperature for 3 h. Wash 5 times with PBST, air dry, seal, and store at 2-8°C away from light.

[0071] (2) Serum incubation: Add 100 μL of diluted porcine serum, including African swine fever serotype 8 (ASFV), pseudorabies virus (PRV), porcine epidemic diarrhea (PEDV), porcine reproductive and respiratory syndrome virus (PRRSV) and classical swine fever virus (CSFV) antibody positive samples to each well and incubate at room temperature for 1 h.

[0072] (3) Incubation with HRP enzyme-labeled secondary antibody: After serum incubation, wash with PBST for 5 times, add 100 μL of diluted HRP enzyme-labeled goat anti-swine IgG (h+L) (KPL Company) into the wells and incubate at room temperature for 30 minutes.

[0073] (4) Color development reaction: After incubation with HRP enzyme-labeled secondary antibody, the wells were washed 5 times with PBST, 50 μL TMB color development solution (KPL) was added to each well, and 2 M H 2 SO 4 Stop solution, use a microplate reader to measure the absorbance of each reaction well at 450nm, and calculate the critical value based on the ELISA data as the standard for subsequent sample positive and negative judgment, that is: OD450 ≥ critical value is judged as positive, OD450 < critical value is judged as negative.

[0074] 2. Experimental Results

[0075] 1. Preparation of recombinant proteins in different expression systems

[0076] The recombinant proteins of the extracellular domain of MBP-CD2v prepared from different expression systems were purified by nickel column. In the SDS-PAGE analysis, it was found that the recombinant protein MBP-CD2v-ED-E prepared from the E. coli expression system was about 65kDa (Line 1), the recombinant protein MBP-CD2v-ED-H5 prepared from the insect baculovirus expression system was about 75kDa (Line 2), and the recombinant protein MBP-CD2v-ED-293 prepared from the 293 expression system was about 105kDa (Line 3) expressed in E. coli, High Five cells and 293F cells, respectively. The results of SDS-PAGE analysis showed that the molecular weights of the recombinant proteins MBP-CD2v-ED-293, MBP-CD2v-ED-H5 and MBP-CD2v-ED-E were different due to the differences in glycosylation modifications in different expression systems ( Figure 1 ).

[0077] 2. Screening of recombinant proteins prepared by different expression systems for ELISA coating

[0078] A variety of recombinant proteins were used as coating antigens for ELISA plate coating. As expected, ASFV-positive serum samples were able to recognize CD2v recombinant proteins from all three expression systems. However, the optical density at 450nm (OD450) of the recombinant protein MBP-CD2v-ED-293 prepared based on the 293 expression system and the recombinant protein MBP-CD2v-ED-H5 prepared based on the insect baculovirus expression system was higher (p < 0.01) than that of the recombinant protein MBP-CD2 v-ED-E prepared based on the Escherichia coli expression system, while there was no significant difference in the detection of positive samples between MBP-CD2v-ED-293 and MBP-CD2v-ED-H5 ( Figure 2 ). In addition, the MBP tag used in ELISA had a high background value of nearly 0.5, which was much higher than the blank control (p < 0.01), resulting in the recombinant MBP-CD2v-ED (serotype 8) not being used in ELISA due to the use of the MBP tag (Figure 2a). Therefore, we used the recombinant protein CD2v-ED-293 without the MBP tag in subsequent tests. CD2v-ED-293 prepared using 293 cells was compared with CD2v-ED-c-Jun-293 and CD2v-ED-GCN4-293. It was found that the ELISA based on CD2v-ED-293 coating had the lowest OD450 value when detecting ASFV-positive samples, and the absorbance value corresponding to the other two recombinant proteins was significantly different (p < 0.01). Subsequently, we established an ELISA scheme based on the CD2v-ED-c-Jun-293 recombinant protein.

[0079] Based on this, the indirect ELISA detection kit determined by the present invention includes the following components: a 96-well detachable enzyme-linked reaction plate coated with an antigen (the antigen is CD2v-ED-c-Jun-293 recombinant protein), a positive control serum (recombinant protein immune serum), a negative control serum (specific pathogen-free pig serum), a goat anti-pig secondary antibody labeled with horseradish peroxidase (purchased from KPL, item number 14-14-06, stock solution 1:7000 times diluted), a 10-fold concentrated PBST washing solution (containing 0.05% Tween 20, 0.01 mol / L, pH 7.4 phosphate buffer), a TMB color developing solution (purchased from KPL, item number 5120-0076), and a stop solution (2 mol / L sulfuric acid solution). In fact, the coating antigen can also be other recombinant proteins mentioned above, such as CD2v-ED-293, CD2v-ED-GCN4-293, etc.

[0080] 3. Determination of critical values ​​and specificity calculation for IgG and IgA detection

[0081] Our ELISA test method can detect IgG and IgA separately by changing the secondary antibody. The anti-ASFV specific IgG commercial kit was used to further confirm the detection of 50 negative control sera (collected before the outbreak of African swine fever in China in 2018). All negative control sera were tested for IgG and IgA using two enzyme-linked immunosorbent assays (ELISAs), and the cutoff value was determined based on the negative sera. The mean OD450 value was calculated. and standard deviation (SD), the critical value is defined as According to the calculation of the OD value of the negative serum sample, the OD450 critical values ​​of IgG and IgA are 0.39 and 0.34 respectively, which are used for the judgment of subsequent samples, that is: in the judgment of IgG positive and negative, OD450 ≥ 0.39 is judged as positive, and OD450 < 0.39 is judged as negative; in the judgment of IgA positive and negative, OD450 ≥ 0.34 is judged as positive, and OD450 < 0.34 is judged as negative. The specificity of IgG and IgA is 100% (50 / 50) and 88.0% (44 / 50) respectively. In general, the most specific method is to detect IgG in serum samples.

[0082] 4. Cross-reactivity test

[0083] Specific detection used two ELISA methods to detect anti-PCV2, PRV, PEDV, PRRSV and CSFV positive sera. The serum samples tested by the two ELISAs did not reach the set critical value, indicating that there was no cross-reaction with other common swine pathogens ( Figure 3 ).

[0084] 5. Compliance test

[0085] We selected 51 clinical sera that tested positive for ASFV using commercial kits and 45 clinically negative sera, and used our established ELISA method to perform IgG and IgA tests on 51 clinical sera that were positive for ASFV, 45 clinically negative sera, and 50 negative control sera collected before the outbreak of African swine fever in China in 2018. All 51 clinical serum samples infected with ASFV were IgG-positive when tested by our ELISA. Among the 45 clinically negative sera, 5 were judged to be positive by our ELISA kit, and all 50 negative control sera collected before the outbreak of African swine fever in China in 2018 were negative. Therefore, the compliance rate was 96.7% [(51+95) / (51+0+5+95)]. Using the same method, but because there was no commercial kit for IgA, we could only use the IgG test results for reference. The compliance rate of IgA detection of IgG-positive samples was 78.1% [(51+95) / (51+27+14+95)].

[0086] 6. Distinguishing antibodies between wild-type and CD2v-deficient strains

[0087] Two standard serum samples were selected from ASFV type 8 wild strain and CD2v gene-deficient strain. When the standard serum was tested at different dilutions, the serum concentration of the wild-type strain was still positive when it reached 1:10240, while the serum concentration of the strain lacking the CD2v gene was always below the critical value and was judged to be negative ( Figure 4 The ELISA detection method based on the CD2v extracellular domain that we established can be used to distinguish antibodies from wild-type and CD2v gene-deficient strains.

[0088] 7. Differentiate ASFV serotypes and have no cross-reaction with other pathogens

[0089] After being coated with the 4-type CD2v extracellular domain onto the ELISA plate, it was subsequently used to detect ASFV-positive serum (serotype 8) and anti-PCV2, PRV, PEDV, PRRSV and CSFV-positive serum samples. The absorbance values ​​obtained were all below the critical value, and no positive was detected ( Figure 5 ). Apparently, the CD2v ectodomain has serotype-specific differences in the detection of ASFV 4 and ASFV 8 IgG. In addition, the serotype 4 CD2v ectodomain did not cross-react with other common swine pathogens.

[0090] In summary, the recombinant protein of the present invention, i.e., inserting MBP tag protein at the N-terminus of the extracellular domain of the CD2v protein of the African swine fever virus and inserting GCN4 motif or c-Jun motif at the C-terminus, can be soluble expressed and purified in mammalian, baculovirus and Escherichia coli expression systems, and has the potential to distinguish wild-type and CD2v-deficient strains and serum-specific, distinguishing ASFV type 4 and type 8 serotypes, and can also detect ASFV antibodies (IgG and IgA) based on ELISA of the CD2v extracellular domain (CD2v-ED-293). Among them, after adding GCN4 or c-Jun to the CD2v extracellular domain for ELISA, compared with the conventional CD2v extracellular domain, the recognition ability of ASFV positive serum samples is significantly improved, and it can be used to establish an indirect ELISA detection kit or an indirect ELISA detection method. The indirect ELISA detection kit and detection method thus established have higher sensitivity and specificity, and are widely used. Sequence Listing <110> Hunan Paizhi Biotechnology Co., Ltd. <120> Recombinant protein based on the extracellular domain of African swine fever virus CD2v protein and its construction method and application <160> 10 <170> SIPOSequenceListing 1.0 <210> 1 <211> 578 <212> PRT <213> Artificial Sequence <400> 1 Met Gly Ser His His His His His Gly Ser Leu Gln Asp Lys Ile 1 5 10 15 Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn 20 25 30 Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys 35 40 45 Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val 50 55 60 Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg 65 70 75 80 Phe Gly Gly Tyr Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp 85 90 95 Lys Ala Phe Gln Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg 100 105 110 Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser 115 120 125 Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu 130 135 140 Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala 145 150 155 160 Leu Met Phe Asn Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala 165 170 175 Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile 180 185 190 Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe 195 200 205 Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr 210 215 220 Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile 225 230 235 240 Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr 245 250 255 Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe 260 265 270 Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu 275 280 285 Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu 290 295 300 Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser 305 310 315 320 Tyr Glu Glu Glu Leu Ala Lys Asp Pro Arg Ile Ala Ala Thr Met Glu 325 330 335 Asn Ala Gln Lys Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala 340 345 350 Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg 355 360 365 Gln Thr Val Asp Glu Ala Leu Lys Asp Ala Gln Thr Asp Tyr Asp Ile 370 375 380 Pro Thr Thr Ile Asp Tyr Trp Val Ser Phe Asn Lys Thr Ile Ile Leu 385 390 395 400 Asp Ser Asn Ile Thr Asn Asp Asn Asn Asp Ile Asn Gly Val Ser Trp 405 410 415 Asn Phe Phe Asn Asn Ser Phe Asn Thr Leu Ala Thr Cys Gly Lys Ala 420 425 430 Gly Asn Phe Cys Glu Cys Ser Asn Tyr Ser Thr Ser Ile Tyr Asn Ile 435 440 445 Thr Asn Asn Cys Ser Leu Thr Ile Phe Pro His Asn Asp Val Phe Asp 450 455 460 Thr Thr Tyr Gln Val Val Trp Asn Gln Ile Ile Asn Tyr Thr Ile Lys 465 470 475 480 Leu Leu Thr Pro Ala Thr Pro Pro Asn Ile Thr Tyr Asn Cys Thr Asn 485 490 495 Phe Leu Ile Thr Cys Lys Lys Asn Asn Gly Thr Asn Thr Asn Ile Tyr 500 505 510 Leu Asn Ile Asn Asp Thr Phe Val Lys Tyr Thr Asn Glu Ser Ile Leu 515 520 525 Glu Tyr Asn Trp Asn Asn Ser Asn Ile Asn Asn Phe Thr Ala Thr Cys 530 535 540 Ile Ile Asn Asn Thr Ile Ser Thr Ser Asn Glu Thr Thr Leu Ile Asn 545 550 555 560 Cys Thr Tyr Leu Thr Leu Ser Ser Asn Tyr Phe Tyr Thr Phe Phe Lys 565 570 575 Leu Tyr <210> 2 <211> 238 <212> PRT <213> Artificial Sequence <400> 2 Met Gly Ser His His His His His His Gly Ser Ile Asp Tyr Trp Val 1 5 10 15 Ser Phe Asn Lys Thr Ile Ile Leu Asp Ser Asn Ile Thr Asn Asp Asn 20 25 30 Asn Asp Ile Asn Gly Val Ser Trp Asn Phe Phe Asn Asn Ser Phe Asn 35 40 45 Thr Leu Ala Thr Cys Gly Lys Ala Gly Asn Phe Cys Glu Cys Ser Asn 50 55 60 Tyr Ser Thr Ser Ile Tyr Asn Ile Thr Asn Asn Cys Ser Leu Thr Ile 65 70 75 80 Phe Pro His Asn Asp Val Phe Asp Thr Thr Tyr Gln Val Val Trp Asn 85 90 95 Gln Ile Ile Asn Tyr Thr Ile Lys Leu Leu Thr Pro Ala Thr Pro Pro 100 105 110 Asn Ile Thr Tyr Asn Cys Thr Asn Phe Leu Ile Thr Cys Lys Lys Asn 115 120 125 Asn Gly Thr Asn Thr Asn Ile Tyr Leu Asn Ile Asn Asp Thr Phe Val 130 135 140 Lys Tyr Thr Asn Glu Ser Ile Leu Glu Tyr Asn Trp Asn Asn Ser Asn 145 150 155 160 Ile Asn Asn Phe Thr Ala Thr Cys Ile Ile Asn Asn Thr Ile Ser Thr 165 170 175 Ser Asn Glu Thr Thr Leu Ile Asn Cys Thr Tyr Leu Thr Leu Ser Ser 180 185 190 Asn Tyr Phe Tyr Thr Phe Phe Lys Leu Tyr Gly Gly Ser Arg Met Lys 195 200 205 Gln Leu Glu Asp Lys Val Glu Glu Leu Leu Ser Lys Asn Tyr His Leu 210 215 220 Glu Asn Glu Val Ala Arg Leu Lys Lys Leu Val Gly Glu Arg 225 230 235 <210> 3 <211> 241 <212> PRT <213> Artificial Sequence <400> 3 Met Gly Ser His His His His His His Gly Ser Ile Asp Tyr Trp Val 1 5 10 15 Ser Phe Asn Lys Thr Ile Ile Leu Asp Ser Asn Ile Thr Asn Asp Asn 20 25 30 Asn Asp Ile Asn Gly Val Ser Trp Asn Phe Phe Asn Asn Ser Phe Asn 35 40 45 Thr Leu Ala Thr Cys Gly Lys Ala Gly Asn Phe Cys Glu Cys Ser Asn 50 55 60 Tyr Ser Thr Ser Ile Tyr Asn Ile Thr Asn Asn Cys Ser Leu Thr Ile 65 70 75 80 Phe Pro His Asn Asp Val Phe Asp Thr Thr Tyr Gln Val Val Trp Asn 85 90 95 Gln Ile Ile Asn Tyr Thr Ile Lys Leu Leu Thr Pro Ala Thr Pro Pro 100 105 110 Asn Ile Thr Tyr Asn Cys Thr Asn Phe Leu Ile Thr Cys Lys Lys Asn 115 120 125 Asn Gly Thr Asn Thr Asn Ile Tyr Leu Asn Ile Asn Asp Thr Phe Val 130 135 140 Lys Tyr Thr Asn Glu Ser Ile Leu Glu Tyr Asn Trp Asn Asn Ser Asn 145 150 155 160 I Have No Asn Phe Thr Ala Thr Cys I Ile I Have Asn Thr Ile Ser Thr 165 170 175 Thr Thr Glu Asn Ile Thr Thr Leu Asn Cys Thr Thr Leu Ser Ser 180 185 190 Asn Tyr Phe Tyr Thr Phe Phe Lys Leu Tyr Gly Gly Ser Leu Glu Glu 195 200 205 Lys Val Lys Thr Leu Lys Ala Gln Asn Serving Glu Leu Ala Serving Thr Ala 210 215 220 Asn With Arg Glu Gln Val Ala Gln With Lys Gln Lys Val Met Asn 225 230 235 240 His <210> 4 <211> 603 <212> DNA <213> African swine fever virus (African swine fever virus) <400> 4 atgggaagcc accaccacca ccaccacgggg tcacatta tcatctggtc caccctgaac 60 cagaccgtgt tcctgaacaa catctttaca attaatgaca catacggcgg actgttctgg 120 aacacatact acgacaacaa ccggagcaac ttcacctatt gtggcatcgc cggcaattac 180 tgcagctgct gcggccacaa tatcagcctt tataatacga ccaacaactg cagcctgatc 240 atctttccaa acaatacaga aatcttcaac agaacctacg agctggtgta cctggacaag 300 aaaatcaact acaccgttaa gctgctcaaa agcgtggaca gccctaccat cacctacaac 360 tgtacaaaca gcctgattac atgtaaaaac aacaacggca caaacgtgaa catctacctg 420 atcatcaaca ataccatcgt gaacgacacc aatggagata tcctgaacta ctactggaac 480 ggcaacaaca atttcaccgc cacatgcatg atcaacaaca ccatcagcag cctgaatgag 540 acagagaaca tcaactgcac caaccccatc ctgaagtacc agaactacct gagcaccctg 600 taa 603 <210> 5 <211> 609 <212> DNA <213> African swine fever virus <400> 5 atgggaagcc accaccacca ccaccacggg tccatcgact actgggtgtc tttcaataag 60 acaatcatcc tggatagcaa catcaccaat gacaacaatg atatcaacgg cgtgagctgg 120 aatttcttta acaattcctt caacaccctg gccacatgcg gcaaggccgg caacttttgc 180 gagtgttcta attactctac cagcatctat aacatcacaa acaattgtag cctgaccatc 240 ttcccacaca atgacgtgtt tgataccaca taccaggtgg tgtggaacca gatcatcaat 300 tatacaatca agctgctgac ccctgccaca ccccctaaca tcacctacaa ctgcacaaat 360 tttctgatca cctgtaagaa gaacaatggc accaacacaa atatctatct gaacatcaat 420 gacaccttcg tgaagtacac aaatgagtcc atcctggagt acaactggaa caactctaac 480 atcaacaact tcaccgccac atgcatcatc aacaatacca tctccacatc taacgagacc 540 acactgatca attgtaccta cctgacactg agctccaact acttctatac cttctttaag 600 ctgtactaa 609 <210> 6 <211> 1161 <212> DNA <213> Artificial Sequence <400> 6 atgggaagcc accaccacca ccaccacggg tccctgcagg acaaaatcga agaaggtaaa 60 ctggtaatct ggattaacgg cgataaaggc tataacggtc tcgctgaagt cggtaagaaa 120 180 ttcccacagg ttgcggcaac tggcgatggc cctgacatta tcttctgggc acacgaccgc 240 tttggtggct acgctcaatc tggcctgttg gctgaaatca ccccggacaa agcgttccag 300 gacaagctgt atccgtttac ctgggatgcc gtacgttaca acggcaagct gattgcttac 360 ccgatcgctg ttgaagcgtt atcgctgatt tataaaaag atctgctgcc gaacccgcca 420 aaaacctggg aagagatccc ggcgctggat aaagaactga aagcgaaagg taagagcgcg 480 ctgatgttca acctgcaaga accgtacttc acctggccgc tgattgctgc tgacggggt 540 tatgcgttca agtatgaaaa cggcaagtac gacattaaag acgtgggcgt ggataacgct 600 ggcgcgaaag cgggtctgac cttcctggtt gacctgatta aaaaaaca catgaatgca 660 gacaccgatt actccatcgc agaagctgcc tttaataaag gcgaaacagc gatgaccatc 720 aacggccccgt gggcatggtc caacatcgac accagcaaag tgaattatgg tgtaacggta 780 ctgccgacct tcaagggtca accatccaaa ccgttcgttg gcgtgctgag cgcaggtatt 840 aacgccgcca gtccgaacaa agagctggca aaagagttcc tcgaaaacta tctgctgact 900 gatgaaggtc tggaagcggt tataaagac aaaccgctgg gtgccgtagc gctgaagtct 960 tacgaggaag agttggcgaa agatccacgt attgccgcca ccatggaaaa cgcccagaaa 1020 ggtgaaatca tgccgaacat cccgcagatg tccgctttct ggtatgccgt gcgtactgcg 1080 gtgatcaacg ccgccagcgg tcgtcagact gtcgatgaag ccctgaaaga cgcgcagact 1140 gattacgata tcccaacgac c 1161 <210> 7 <211> 99 <212> DNA <213> Artificial Sequence <400> 7 cggatgaagc aactggaaga taaggttgag gaactgctga gcaagaacta ccacctggag 60 aacgaggttg ccagactgaa aaaactcgtg ggcgagcgg 99 <210> 8 <211> 108 <212> DNA <213> Artificial Sequence <400> 8 ctggaagaga aggtcaagac cctgaaggct cagaactccg agctggccag cacagccaat 60 atgctgcggg aacaggtggc ccagctgaag cagaaggtga tgaaccac 108 <210> 9 <211> 190 <212> PRT <213> African swine fever virus <400> 9 Met Asn Ile Ile Ile Trp Ser Thr Leu Asn Gln Thr Val Phe Leu Asn 1 5 10 15 Asn Ile Phe Thr Ile Asn Asp Thr Tyr Gly Gly Leu Phe Trp Asn Thr 20 25 30 Tyr Tyr Asp Asn Asn Arg Ser Asn Phe Thr Tyr Cys Gly Ile Ala Gly 35 40 45 Asn Tyr Cys Ser Cys Cys Gly His Asn Ile Ser Leu Tyr Asn Thr Thr 50 55 60 Asn Asn Cys Ser Leu Ile Ile Phe Pro Asn Asn Thr Glu Ile Phe Asn 65 70 75 80 Arg Thr Tyr Glu Leu Val Tyr Leu Asp Lys Lys Ile Asn Tyr Thr Val 85 90 95 Lys Leu Leu Lys Ser Val Asp Ser Pro Thr Ile Thr Tyr Asn Cys Thr 100 105 110 Asn Ser Leu Ile Thr Cys Lys Asn Asn Asn Gly Thr Asn Val Asn Ile 115 120 125 Tyr Leu Ile Ile Asn Asn Thr Ile Val Asn Asp Thr Asn Gly Asp Ile 130 135 140 Leu Asn Tyr Tyr Trp Asn Gly Asn Asn Asn Phe Thr Ala Thr Cys Met 145 150 155 160 Ile Asn Asn Thr Ile Ser Ser Leu Asn Glu Thr Glu Asn Ile Asn Cys 165 170 175 Thr Asn Pro Ile Leu Lys Tyr Gln Asn Tyr Leu Ser Thr Leu 180 185 190 <210> 10 <211> 192 <212> PRT <213> African swine fever virus <400> 10 Met Ile Asp Tyr Trp Val Ser Phe Asn Lys Thr Ile Ile Leu Asp Ser 1 5 10 15 Asn Ile Thr Asn Asp Asn Asn Asp Ile Asn Gly Val Ser Trp Asn Phe 20 25 30 Phe Asn Asn Ser Phe Asn Thr Leu Ala Thr Cys Gly Lys Ala Gly Asn 35 40 45 Phe Cys Glu Cys Ser Asn Tyr Ser Thr Ser Ile Tyr Asn Ile Thr Asn 50 55 60 Asn Cys Ser Leu Thr Ile Phe Pro His Asn Asp Val Phe Asp Thr Thr 65 70 75 80 Tyr Gln Val Val Trp Asn Gln Ile Ile Asn Tyr Thr Ile Lys Leu Leu 85 90 95 Thr Pro Ala Thr Pro Pro Asn Ile Thr Tyr Asn Cys Thr Asn Phe Leu 100 105 110 Ile Thr Cys Lys Lys Asn Asn Gly Thr Asn Thr Asn Ile Tyr Leu Asn 115 120 125 Ile Asn Asp Thr Phe Val Lys Tyr Thr Asn Glu Ser Ile Leu Glu Tyr 130 135 140 Asn Trp Asn Asn Ser Asn Ile Asn Asn Phe Thr Ala Thr Cys Ile Ile 145 150 155 160 Asn Asn Thr Ile Ser Thr Ser Asn Glu Thr Thr Leu Ile Asn Cys Thr 165 170 175 Tyr Leu Thr Leu Ser Ser Asn Tyr Phe Tyr Thr Phe Phe Lys Leu Tyr 180 185 190

Claims

1. A recombinant protein based on the extracellular domain of African swine fever virus CD2v protein, characterized in that: include: The extracellular domain of African swine fever virus CD2v protein, a GCN4 motif or a c-Jun motif is inserted into the C-terminus of the extracellular domain of African swine fever virus CD2v protein; the amino acid sequence of the recombinant protein formed by inserting the GCN4 motif into the C-terminus of the extracellular domain of African swine fever virus CD2v protein is shown in SEQ ID NO: 2, and the amino acid sequence of the recombinant protein formed by inserting the c-Jun motif into the C-terminus of the extracellular domain of African swine fever virus CD2v protein is shown in SEQ ID NO:

3.

2. A method for constructing a recombinant protein based on the extracellular domain of African swine fever virus CD2v protein as claimed in claim 1, characterized in that: The method comprises the following steps: fusing a nucleotide fragment encoding the extracellular domain of the African swine fever virus CD2v protein with a nucleotide fragment encoding the GCN4 motif or the c-Jun motif, subcloning the fragments into a vector, and expressing the obtained expression plasmid in 293F cells to obtain the recombinant protein.

3. Use of the recombinant protein as claimed in claim 1 in establishing an indirect ELISA detection method.

4. The use according to claim 3, characterized in that: The process of establishing the indirect ELISA detection method includes the following steps: using the recombinant protein as a coating antigen, diluting it with PBS and adding it to the wells of the ELISA plate for coating overnight, then blocking, serum incubation, IgG and IgA HRP enzyme-labeled secondary antibody incubation, color development reaction, and then using an enzyme reader to measure the absorbance of the reaction solution at 450 nm, and calculating the critical value based on the ELISA data as a standard for subsequent sample positive and negative judgment, which is used to establish the indirect ELISA detection method.

5. An indirect ELISA detection kit, characterized in that, include: A 96-well detachable enzyme-linked reaction plate coated with an antigen, a positive control serum, a negative control serum, a goat anti-pig secondary antibody labeled with horseradish peroxidase, a PBST washing solution, a TMB color developing solution and a stop solution, wherein the antigen is the recombinant protein according to claim 1.